2024-03-312025-03-302025-03-30falseSC460311BONHARD MEDICAL LIMITED2025-07-0286210falseiso4217:GBPxbrli:pureSC4603112024-03-30SC4603112025-03-30SC4603112024-03-312025-03-30SC4603112023-03-30SC4603112024-03-30SC4603112023-03-312024-03-30SC460311bus:SmallEntities2024-03-312025-03-30SC460311bus:AuditExempt-NoAccountantsReport2024-03-312025-03-30SC460311bus:FullAccounts2024-03-312025-03-30SC460311bus:PrivateLimitedCompanyLtd2024-03-312025-03-30SC460311core:WithinOneYear2025-03-30SC460311core:AfterOneYear2025-03-30SC460311core:WithinOneYear2024-03-30SC460311core:AfterOneYear2024-03-30SC460311core:ShareCapital2025-03-30SC460311core:SharePremium2025-03-30SC460311core:RevaluationReserve2025-03-30SC460311core:OtherReservesSubtotal2025-03-30SC460311core:RetainedEarningsAccumulatedLosses2025-03-30SC460311core:ShareCapital2024-03-30SC460311core:SharePremium2024-03-30SC460311core:RevaluationReserve2024-03-30SC460311core:OtherReservesSubtotal2024-03-30SC460311core:RetainedEarningsAccumulatedLosses2024-03-30SC460311core:LandBuildings2025-03-30SC460311core:PlantMachinery2025-03-30SC460311core:Vehicles2025-03-30SC460311core:FurnitureFittings2025-03-30SC460311core:OfficeEquipment2025-03-30SC460311core:NetGoodwill2025-03-30SC460311core:IntangibleAssetsOtherThanGoodwill2025-03-30SC460311core:ListedExchangeTraded2025-03-30SC460311core:UnlistedNon-exchangeTraded2025-03-30SC460311core:LandBuildings2024-03-30SC460311core:PlantMachinery2024-03-30SC460311core:Vehicles2024-03-30SC460311core:FurnitureFittings2024-03-30SC460311core:OfficeEquipment2024-03-30SC460311core:NetGoodwill2024-03-30SC460311core:IntangibleAssetsOtherThanGoodwill2024-03-30SC460311core:ListedExchangeTraded2024-03-30SC460311core:UnlistedNon-exchangeTraded2024-03-30SC460311core:LandBuildings2024-03-312025-03-30SC460311core:PlantMachinery2024-03-312025-03-30SC460311core:Vehicles2024-03-312025-03-30SC460311core:FurnitureFittings2024-03-312025-03-30SC460311core:OfficeEquipment2024-03-312025-03-30SC460311core:NetGoodwill2024-03-312025-03-30SC460311core:IntangibleAssetsOtherThanGoodwill2024-03-312025-03-30SC460311core:ListedExchangeTraded2024-03-312025-03-30SC460311core:UnlistedNon-exchangeTraded2024-03-312025-03-30SC460311core:MoreThanFiveYears2024-03-312025-03-30SC460311core:Non-currentFinancialInstruments2025-03-30SC460311core:Non-currentFinancialInstruments2024-03-30SC460311dpl:CostSales2024-03-312025-03-30SC460311dpl:DistributionCosts2024-03-312025-03-30SC460311core:LandBuildings2024-03-312025-03-30SC460311core:PlantMachinery2024-03-312025-03-30SC460311core:Vehicles2024-03-312025-03-30SC460311core:FurnitureFittings2024-03-312025-03-30SC460311core:OfficeEquipment2024-03-312025-03-30SC460311dpl:AdministrativeExpenses2024-03-312025-03-30SC460311core:NetGoodwill2024-03-312025-03-30SC460311core:IntangibleAssetsOtherThanGoodwill2024-03-312025-03-30SC460311dpl:GroupUndertakings2024-03-312025-03-30SC460311dpl:ParticipatingInterests2024-03-312025-03-30SC460311dpl:GroupUndertakingscore:ListedExchangeTraded2024-03-312025-03-30SC460311core:ListedExchangeTraded2024-03-312025-03-30SC460311dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-03-312025-03-30SC460311core:UnlistedNon-exchangeTraded2024-03-312025-03-30SC460311dpl:CostSales2023-03-312024-03-30SC460311dpl:DistributionCosts2023-03-312024-03-30SC460311core:LandBuildings2023-03-312024-03-30SC460311core:PlantMachinery2023-03-312024-03-30SC460311core:Vehicles2023-03-312024-03-30SC460311core:FurnitureFittings2023-03-312024-03-30SC460311core:OfficeEquipment2023-03-312024-03-30SC460311dpl:AdministrativeExpenses2023-03-312024-03-30SC460311core:NetGoodwill2023-03-312024-03-30SC460311core:IntangibleAssetsOtherThanGoodwill2023-03-312024-03-30SC460311dpl:GroupUndertakings2023-03-312024-03-30SC460311dpl:ParticipatingInterests2023-03-312024-03-30SC460311dpl:GroupUndertakingscore:ListedExchangeTraded2023-03-312024-03-30SC460311core:ListedExchangeTraded2023-03-312024-03-30SC460311dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-03-312024-03-30SC460311core:UnlistedNon-exchangeTraded2023-03-312024-03-30SC460311core:NetGoodwill2025-03-30SC460311core:IntangibleAssetsOtherThanGoodwill2025-03-30SC460311core:LandBuildings2025-03-30SC460311core:PlantMachinery2025-03-30SC460311core:Vehicles2025-03-30SC460311core:FurnitureFittings2025-03-30SC460311core:OfficeEquipment2025-03-30SC460311core:AfterOneYear2025-03-30SC460311core:WithinOneYear2025-03-30SC460311core:ListedExchangeTraded2025-03-30SC460311core:UnlistedNon-exchangeTraded2025-03-30SC460311core:ShareCapital2025-03-30SC460311core:SharePremium2025-03-30SC460311core:RevaluationReserve2025-03-30SC460311core:OtherReservesSubtotal2025-03-30SC460311core:RetainedEarningsAccumulatedLosses2025-03-30SC460311core:NetGoodwill2024-03-30SC460311core:IntangibleAssetsOtherThanGoodwill2024-03-30SC460311core:LandBuildings2024-03-30SC460311core:PlantMachinery2024-03-30SC460311core:Vehicles2024-03-30SC460311core:FurnitureFittings2024-03-30SC460311core:OfficeEquipment2024-03-30SC460311core:AfterOneYear2024-03-30SC460311core:WithinOneYear2024-03-30SC460311core:ListedExchangeTraded2024-03-30SC460311core:UnlistedNon-exchangeTraded2024-03-30SC460311core:ShareCapital2024-03-30SC460311core:SharePremium2024-03-30SC460311core:RevaluationReserve2024-03-30SC460311core:OtherReservesSubtotal2024-03-30SC460311core:RetainedEarningsAccumulatedLosses2024-03-30SC460311core:NetGoodwill2023-03-30SC460311core:IntangibleAssetsOtherThanGoodwill2023-03-30SC460311core:LandBuildings2023-03-30SC460311core:PlantMachinery2023-03-30SC460311core:Vehicles2023-03-30SC460311core:FurnitureFittings2023-03-30SC460311core:OfficeEquipment2023-03-30SC460311core:AfterOneYear2023-03-30SC460311core:WithinOneYear2023-03-30SC460311core:ListedExchangeTraded2023-03-30SC460311core:UnlistedNon-exchangeTraded2023-03-30SC460311core:ShareCapital2023-03-30SC460311core:SharePremium2023-03-30SC460311core:RevaluationReserve2023-03-30SC460311core:OtherReservesSubtotal2023-03-30SC460311core:RetainedEarningsAccumulatedLosses2023-03-30SC460311core:AfterOneYear2024-03-312025-03-30SC460311core:WithinOneYear2024-03-312025-03-30SC460311core:Non-currentFinancialInstrumentscore:CostValuation2024-03-312025-03-30SC460311core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-312025-03-30SC460311core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-312025-03-30SC460311core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-312025-03-30SC460311core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-312025-03-30SC460311core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-312025-03-30SC460311core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-312025-03-30SC460311core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-312025-03-30SC460311core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-312025-03-30SC460311core:Non-currentFinancialInstrumentscore:CostValuation2025-03-30SC460311core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-03-30SC460311core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-03-30SC460311core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-03-30SC460311core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-03-30SC460311core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-03-30SC460311core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-03-30SC460311core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-03-30SC460311core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-03-30SC460311core:Non-currentFinancialInstrumentscore:CostValuation2024-03-30SC460311core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-03-30SC460311core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-03-30SC460311core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-03-30SC460311core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-03-30SC460311core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-03-30SC460311core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-03-30SC460311core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-03-30SC460311core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-03-30SC460311bus:Director12024-03-312025-03-30SC460311bus:Director22024-03-312025-03-30SC460311core:FurnitureFittingsToolsEquipment2024-03-30SC460311core:FurnitureFittingsToolsEquipment2024-03-312025-03-30SC460311core:FurnitureFittingsToolsEquipment2025-03-30

BONHARD MEDICAL LIMITED

Registered Number
SC460311
(Scotland)

Unaudited Financial Statements for the Year ended
30 March 2025

BONHARD MEDICAL LIMITED
Company Information
for the year from 31 March 2024 to 30 March 2025

Directors

Dr Andrew John Ashworth
Lorna Elizabeth Black Ashworth

Registered Address

Bonhard House
Bonhard House
Bo'Ness
EH51 9RR

Registered Number

SC460311 (Scotland)
BONHARD MEDICAL LIMITED
Balance Sheet as at
30 March 2025

Notes

2025

2024

£

£

£

£

Fixed assets
Intangible assets330,07645,113
Tangible assets4159,07666,875
189,152111,988
Current assets
Debtors554,65157,230
Cash at bank and on hand65,710149,618
120,361206,848
Creditors amounts falling due within one year6(18,434)(19,300)
Net current assets (liabilities)101,927187,548
Total assets less current liabilities291,079299,536
Provisions for liabilities(32,425)(14,106)
Net assets258,654285,430
Capital and reserves
Called up share capital1,000100
Profit and loss account257,654285,330
Shareholders' funds258,654285,430
The financial statements were approved and authorised for issue by the Board of Directors on 2 July 2025, and are signed on its behalf by:
Dr Andrew John Ashworth
Director
Registered Company No. SC460311
BONHARD MEDICAL LIMITED
Notes to the Financial Statements
for the year ended 30 March 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Turnover policy
Turnover represents gross invoiced provision of services in the year.
Employee benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.
Current taxation
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Intangible assets
Development expenditure is capitalised when eligible costs are incurred. The resulting intangible asset is amortised over three years once the commercial production in respect of these costs has commenced.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows: Plant and machinery - 50% on cost and 25% on cost Fixtures and fittings - 25% on reducing balance Office Equipment - 10% on cost Vehicles - 25% on reducing balance Building - 2% on cost
Finance leases and hire purchase contracts
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.
2.Average number of employees

20252024
Average number of employees during the year22
3.Intangible assets

Other

Total

££
Cost or valuation
At 31 March 2445,11345,113
At 30 March 2545,11345,113
Amortisation and impairment
Charge for year15,03715,037
At 30 March 2515,03715,037
Net book value
At 30 March 2530,07630,076
At 30 March 2445,11345,113
4.Tangible fixed assets

Land & buildings

Plant & machinery

Vehicles

Fixtures & fittings

Office Equipment

Total

££££££
Cost or valuation
At 31 March 24-13,866-9,39894,940118,204
Additions81,1963,88422,824--107,904
At 30 March 2581,19617,75022,8249,39894,940226,108
Depreciation and impairment
At 31 March 24-12,641-7,54231,14651,329
Charge for year1,0831,4674,7554257,97315,703
At 30 March 251,08314,1084,7557,96739,11967,032
Net book value
At 30 March 2580,1133,64218,0691,43155,821159,076
At 30 March 24-1,225-1,85663,79466,875
5.Debtors: amounts due within one year

2025

2024

££
Other debtors53,02557,075
Prepayments and accrued income1,626155
Total54,65157,230
6.Creditors: amounts due within one year

2025

2024

££
Taxation and social security12,49716,520
Other creditors3,783775
Accrued liabilities and deferred income2,1542,005
Total18,43419,300
7.Related party transactions
Other creditors due within one year include amounts due to Mr G Ashworth, son of Director Dr A Ashworth of £3,783 (2024: £775). No interest is charged on this amount.